Cellular and molecular mechanisms of inflammation of esophageal mucosa under different clinical course of gastroesophageal reflux disease and its complications


Cite item

Full Text

Abstract

The review presents modern data on the cellular and molecular mechanisms of inflammatory changes of esophageal mucosa exposed to different types of reluctate (gastric, biliary or duodenal/mixed). The authors describe data on key mediators of inflammation in gastroesophageal reflux disease (GERD) and their major cellular sources, changes of the immune profile of patients. Discusses the possible impact of changes in the cellular and molecular components in the development of the inflammatory response in the esophagus on the clinical features of GERD and its therapy-refractory forms.

About the authors

S V Lyamina

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: svlvs@mail.ru
д.м.н., проф. каф. патологической физиологии, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии, н.с. лаб. функциональных методов исследования в гастроэнтерологии Moscow, Russia

I V Maev

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

академик РАН, д.м.н., проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии Moscow, Russia

O V Kladovikova

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

аспирант каф. пропедевтики внутренних болезней и гастроэнтерологии Moscow, Russia

I Yu Malyshev

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

д.м.н., проф., зав. каф. патологической физиологии Moscow, Russia

References

  1. Souza R.F. Reflux esophagitis and its role in the pathogenesis of Barrett’s metaplasia. J Gastroenterol. 2017;52:767-76. doi: 10.1007/s00535-017-1342-1
  2. Spechler S.J, Souza R.F. Barrett’s esophagus. N Engl J Med. 2014; 371:836-45.
  3. Плотникова Е.Ю., Вологжанина Л.Г., Самсонов А.А., Андреев Д.Н., Самсонова О.А. Течение ГЭРБ по результатам ретроспективного 5-летнего наблюдения. Фарматека. 2016;(6):64-8.
  4. El-Serag H.B, Ergun G.A, Pandolfino J, Fitzgerald S, Tran T, Kramer J.R. Obesity increases oesophageal acid exposure. Gut. 2007;56(6):749-55. doi: 10.1136/gut.2006.100263
  5. Евсютина Ю.В. Клинико - морфологические характеристики гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы: Дисс.. канд. мед. наук. Москва: Первый МГМУ им. И.М. Сеченова; 2015. Доступно по ссылке: http://www.gastroscan.ru/disser/evsytina-yv-diss.pdf.
  6. Vakil N, van Zanten S.V, Kahrilas P, Dent J, Jones R; Global Consensus Group. Montreal definition and classification of gastroesophageal reflux disease: a global evidence - based consensus. Am J Gastroenterol. 2006;101(8):1900-20; quiz 1943.
  7. Ambarus C.A, Krausz S, van Eijk M, Hamann J, Radstake T.R, Reedquist K.A, Tak P.P, Baeten D.L. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Meth. 2012;375(1-2):196-206. doi: 10.1016/j.jim.2011.10.013
  8. Fritz J, Murphy B.S, Sundareshan V, Cory T.J, Hayes D.I, Anstead M.I, Feola D.J. M1 and M2 Macrophage activation. Azithromycin alters macrophage phenotype. J Antimicrob Chemother. 2008;61(3):554-60.
  9. Maev IV, Vuychnova E.S, Schekina M.I. Gastroesophageal reflux disease - Disease of XXI century. Attending Doctor. 2004;4:10-14.
  10. Трухманов А.С. Пищевод Барретта: эпидемиология, патогенез, клиническое течение и профилактика. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2002;12(5):59-62.
  11. Ивашкин В.Т., Маев И.В., Трухманов А.С., Баранская Е.К., Дронова О.Б., Зайратьянц О.В., Пасечников В.Д., Сайфутдинов Р.Г., Шептулин А.А., Кучерявый Ю.А., Лапина Т.Л., Сторонова О.А., Кайбышева В.О. Гастроэзофагеальная рефлюксная болезнь. Клинические рекомендации. Москва: Российская гастроэнтерологическая ассоциация; 2014; 23 с.
  12. Katz P, Gerson L, Vela M. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2013;108:308-28. doi: 10.1038/ajg.2012.444
  13. Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro - oesophageal reflux disease. Aliment Pharmacol Ther. 2006;24 Suppl 2:10-6.
  14. Vaezi M.F, Singh S, Richter J.E. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology. 1995;108(6):1897-907.
  15. Karamanolis G, Vanuytsel T, Sifrim D, Bisschops R, Arts J, Caenepeel P, Dewulf D, Tack J. Yield of 24-h esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci. 2008;53:2387-93. doi: 10.1007/s10620-007-0186-6
  16. Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single - dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981-8.
  17. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner P.B.Jr. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci. 2005;50:81-5.
  18. Kauer W.K, Peters J.H, De Meester T.R, Ireland A.P, Bremner C.G, Hagen J.A. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re - emphasized. Ann Surg. 1995;222(4):525-31.
  19. Vela M.F, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz P.O, Castell D.O. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599-606.
  20. Sifrim D, Holloway R, Silny J, Xin Z, Tack J, Lerut A, Janssens J. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-h pH-impedance recordings. Gastroenterology. 2001;120:1588-98.
  21. Bredenoord A.L, Smout A.J. Refractory gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol. 2008;20:217-23.
  22. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell D.O. Acid and non - acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance - pH monitoring. Gut. 2006;55(10):1398-402.
  23. Zerbib F, Roman S, Ropert A, des Varannes S.B, Pouderoux P, Chaput U, Mion F, Vérin E, Galmiche J.P, Sifrim D. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006;101(9):1956-63.
  24. Katz P, Gideon R.M, Tutuian R. Reflux symptoms on twice daily (BID) proton pump inhibitor (PPI) associated with non acid reflux; a manifestation of hypersensitive esophagus? Am J Gastroenterol. 2005;128: A-130, 31-3.
  25. Кайбышева В.О., Сторонова О.А., Трухманов А.С., Ивашкин В.Т. Возможности внутрипищеводной рН-импедансометрии в диагностике ГЭРБ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013;23(2):4-16.
  26. Rossetti G, Limongelli P, Cimmino M, Napoletano D, Bondanese M.C, Romano G, Pratilas M, Guerriero L, Orlando F, Conzo G, Amato B, Docimo G, Tolone S, Brusciano L, Docimo L, Fei L. Outcome of medical and surgical therapy of GERD: predictive role of quality of life scores and instrumental evaluation. Int J Surg. 2014;12 Suppl 1:S112-6. doi: 10.1016/j.ijsu.2014.05.034
  27. Евсютина Ю.В., Трухманов А.С. Новый взгляд на проблему гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(5):4-9.
  28. Лямина С.В., Маев И.В., Юренев Г.Л., Малышев И.Ю. Бронхиальная астма и гастроэзофагеальная рефлюксная болезнь: взгляд клинициста и патофизиолога. Терапевтический архив. 2011;(6):73-8.
  29. Rieder F, Biancani P, Harnett K, Yerian L, Falk G.W. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298:571-81.
  30. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol Gastrointest Liver Physiol. 1997;273:769-75.
  31. O’Shaughnessy J.A, Kelloff G.J, Gordon G.B, Dannenberg A.J, Hong W.K, Fabian C.J, Sigman C.C, Bertagnolli M.M, Stratton S.P, Lam S, Nelson W.G, Meyskens F.L, Alberts D.S, Follen M, Rustgi A.K, Papadimitrakopoulou V, Scardino P.T, Gazdar A.F, Wattenberg L.W, Sporn M.B, Sakr W.A, Lippman S.M, von Hoff D.D. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002;8:314-46.
  32. Fornari F, Blondeau K, Mertens V, Tack J, Sifrim D. Nocturnal gastroesophageal reflux revisited by impedance - pH monitoring. J Neurogastroenterol Motility. 2011;17(2):148-57. doi: 10.5056/jnm.2011
  33. Karamanolis G.P, Sifrim D. Patients with refractory gastroesophageal reflux disease: diagnostic tools. Ann Gastroenterol: Quarterly publication of the Hellenic Society of Gastroenterology. 2013;26(1):6-10.
  34. Isomoto H, Inoue K, Kohno S. Interleukin-8 levels in esophageal mucosa and long - term clinical outcome of patients with reflux esophagitis. Scand J Gastroenterol. 2007;42(3):410-1.
  35. Cheng L, Cao W, Behar J, Fiocchi C, Biancani P, Harnett K.M. Acid - induced release of platelet - activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J Pharmacol Exper Ther. 2006;319(1):117-26.
  36. Kohata Y, Fujiwara Y, Machida H, Okazaki H, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Tominaga K, Wei M, Wanibuchi H, Arakawa T. Role of Th-2 cytokines in the development of Barrett's esophagus in rats. J Gastroenterol. 2011;46(7):883-93. doi: 10.1007/ s00535-011-0405-y
  37. Zhong Y.Q, Lin Y, Xu Z. Expression of IFN-γ and IL-4 in the esophageal mucosa of patients with reflux esophagitis and Barrett's esophagus and their relationship with endoscopic and histologic grading. Dig Dis Sci. 2011;56(10):2865-70. doi: 10.1007/s10620-011-1696-9
  38. Isomoto H, Saenko V.A, Kanazawa Y, Nishi Y, Ohtsuru A, Inoue K, Akazawa Y, Takeshima F, Omagari K, Miyazaki M, Mizuta Y, Murata I, Yamashita S, Kohno S. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy - negative gastroesophageal reflux disease. Am J Gastroenterol. 2004;99(4):589-97.
  39. O'Riordan J.M, Abdel-Latif M.M, Ravi N, Mc Namara D, Byrne P.J, Mc Donald G.S, Keeling P.W, Kelleher D, Reynolds J.V. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation - metaplasia - dysplasia - adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100(6):1257-64.
  40. Williams I.R, Kupper T.S. Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci. 1996;58(18):1485-507.
  41. Ghazizadeh M, Tosa M, Shimizu H, Hyakusoku H, Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol. 2007;127(1):98-105.
  42. Lawrance I.C, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis. 2001;7(3):226-36.
  43. Roth M, Nauck M, Yousefi S, Tamm M, Blaser K, Perruchoud A.P, Simon H.U. Platelet - activating factor exerts mitogenic activity and stimulates expression of interleukin 6 and interleukin 8 in human lung fibroblasts via binding to its functional receptor. J Exper Med. 1996;184(1):191-201.
  44. Tabata C, Kubo H, Tabata R, Wada M, Sakuma K, Ichikawa M, Fujita S, Mio T, Mishima M. All - trans retinoic acid modulates radiation - induced proliferation of lung fibroblasts via IL-6/IL-6R system. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L597-606.
  45. Vesey D.A, Cheung C, Cuttle L, Endre Z, Gobe G, Johnson D.W. Interleukin-1beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor - beta - dependent mechanism. J Lab Clin Med. 2002;140(5):342-50.
  46. Fitzgerald R.C, Onwuegbusi B.A, Bajaj-Elliott M, Saeed I.T, Burnham W.R, Farthing M.J. Diversity in the esophageal phenotypic response to gastroesophageal reflux: immunological determinants. Gut. 2002;50: 451-9.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies